Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Arthritis Rheumatol. 2021 May 31;73(7):1334–1340. doi: 10.1002/art.41640

Figure 3:

Figure 3:

Canakinumab treated sJIA patients either up- or downregulate a type I IFN gene signature. Heatmap shows the fold change (+3 to −3) of type I IFN genes from day 0 to day 3 in non-responders and strong clinical responders. Most patients, regardless of response, either up- or downregulate this signature.